24.84
-1.51 (-5.73%)
| Previous Close | 26.35 |
| Open | 23.98 |
| Volume | 891,726 |
| Avg. Volume (3M) | 653,771 |
| Market Cap | 2,474,282,496 |
| Price / Sales | 7.94 |
| Price / Book | 3.67 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2024 - 11 Nov 2024 |
| Profit Margin | -92.44% |
| Operating Margin (TTM) | -75.68% |
| Diluted EPS (TTM) | -3.10 |
| Quarterly Revenue Growth (YOY) | 45.90% |
| Total Debt/Equity (MRQ) | 11.88% |
| Current Ratio (MRQ) | 3.46 |
| Return on Assets (TTM) | -21.13% |
| Return on Equity (TTM) | -36.46% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Zai Lab Limited | Bearish | Bearish |
Stockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | 4.0 |
| Average | 0.88 |
|
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Core |
| % Held by Insiders | 2.18% |
| % Held by Institutions | 45.82% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Segantii Capital Management Ltd | 31 Mar 2024 | 1,555,931 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |